|
Adcock Ingram (AIP) financial results for year ending 30 June 2018
Date: 29 Aug 2018 Category: Stock Market Price per share: R69.50 |
Related Topics |
|
We take a look at the financial results of pharmaceutical manufacturer Adcock Ingram for the financial year ending June 2018. A few highlights include:
|
|
Background on Adcock Ingram (AIP)
Adcock Ingram is a leading South African pharmaceutical manufacturer, listed on the Johannesburg Stock Exchange. The Company manufactures, markets and distributes a wide range of healthcare products. The company is a leading supplier to both the private and public sectors of the market. Adcock Ingram is a level 3 B-BBEE contributor.
Adcock Ingram is ranked as the second largest manufacturer in the private pharmaceutical market and is the second largest supplier to the public sector. Of note is the major share of the critical care market held by the company, being the largest supplier of critical care products to the public sector and hospitals. Adcock Ingram is a committed supplier of antiretroviral (ARV) medicines to the public sector through the highly competitive tender system.
The Consumer division competes in the Fast Moving Consumer Goods (FMCG) space. Iconic brands such as Panado and Compral have given the Company a leadership position in the analgesic market. The product portfolio includes cough and cold preparations, energy supplements, digestive well-being medications, vitamins and feminine hygiene products.
The Over the Counter (OTC) division competes in the self-medication pharmacy and FMCG sectors of the market, with a complement of 88 premium and economy brands. Well-known brands include Adco-Dol, Corenza C and Allergex. The portfolio includes pain, cough and cold, allergy, digestive well-being and energy medications.
The Prescription division markets medicines that are prescribed by medical practitioners and dispensed against a prescription. The division markets a range of quality and affordable generic medicines, including a portfolio of antiretroviral medicines. Partnerships with multinational pharmaceutical companies continue to augment the comprehensive portfolio of originator medicines marketed by the division.
The Critical Care division is a leading supplier of hospital and critical care products offered through multiple portfolios and across wide-ranging customer channels. A long-term agreement with Baxter has positioned Adcock Ingram as the leading supplier in critical care products to the private and public sectors. In a 2016 agreement, the Critical Care division gained the commercial rights to the Pharma-Q range, which is predominantly injectables and complementary to the Critical Care range.
Adcock Ingram is ranked as the second largest manufacturer in the private pharmaceutical market and is the second largest supplier to the public sector. Of note is the major share of the critical care market held by the company, being the largest supplier of critical care products to the public sector and hospitals. Adcock Ingram is a committed supplier of antiretroviral (ARV) medicines to the public sector through the highly competitive tender system.
The Consumer division competes in the Fast Moving Consumer Goods (FMCG) space. Iconic brands such as Panado and Compral have given the Company a leadership position in the analgesic market. The product portfolio includes cough and cold preparations, energy supplements, digestive well-being medications, vitamins and feminine hygiene products.
The Over the Counter (OTC) division competes in the self-medication pharmacy and FMCG sectors of the market, with a complement of 88 premium and economy brands. Well-known brands include Adco-Dol, Corenza C and Allergex. The portfolio includes pain, cough and cold, allergy, digestive well-being and energy medications.
The Prescription division markets medicines that are prescribed by medical practitioners and dispensed against a prescription. The division markets a range of quality and affordable generic medicines, including a portfolio of antiretroviral medicines. Partnerships with multinational pharmaceutical companies continue to augment the comprehensive portfolio of originator medicines marketed by the division.
The Critical Care division is a leading supplier of hospital and critical care products offered through multiple portfolios and across wide-ranging customer channels. A long-term agreement with Baxter has positioned Adcock Ingram as the leading supplier in critical care products to the private and public sectors. In a 2016 agreement, the Critical Care division gained the commercial rights to the Pharma-Q range, which is predominantly injectables and complementary to the Critical Care range.
Percent change: